{"id":18252,"date":"2026-07-26T13:08:11","date_gmt":"2026-07-26T20:08:11","guid":{"rendered":"https:\/\/www.alkegen.com\/?p=18252"},"modified":"2026-07-26T13:08:11","modified_gmt":"2026-07-26T20:08:11","slug":"chapter-11-filing-announcement","status":"publish","type":"post","link":"https:\/\/www.alkegen.com\/de\/chapter-11-filing-announcement\/","title":{"rendered":"Alkegen Commences Prepackaged Chapter 11 Process to Implement Previously Announced Restructuring Support Agreement"},"content":{"rendered":"

Company enters chapter 11 with overwhelming support from key financial partners, including 99% of first lien and 80% of second lien holders<\/em><\/p>\n\n\n\n

Expected to eliminate approximately $3.1 billion of debt and emerge with approximately $200 million of liquidity, positioning the company for continued industry leadership<\/em><\/p>\n\n\n\n

Company secures $315 million in new money debtor-in-possession (\u201cDIP\u201d) financing to support ordinary course operations with no anticipated disruption to employees, customers, vendors, or partners<\/em><\/p>\n\n\n\n

IRVING, Texas, July 26, 2026 \u2014 Alkegen (the \u201cCompany\u201d), a leading specialty materials manufacturer, today announced that it has voluntarily commenced prepackaged chapter 11 cases in the U.S. Bankruptcy Court for the Northern District of Texas to implement the Restructuring Support Agreement (“RSA”) that was previously announced<\/a> on July 20, 2026.<\/p>\n\n\n\n

Under the terms of the RSA, Alkegen will eliminate approximately $3.1 billion of total debt and meaningfully improve its capital structure, positioning the Company for continued industry leadership. Alkegen enters this process with the committed support of its key financial partners and has secured $315 million in new money debtor-in-possession (\u201cDIP\u201d) financing. Upon Court approval, the DIP financing will provide the necessary capital to support the business, maintain existing operations, and meet commitments to Alkegen\u2019s partners throughout the restructuring process.  <\/p>\n\n\n\n

“Today’s filing marks an important milestone in implementing our financial restructuring,” said Brian Whittman, Chief Executive Officer of Alkegen. “We have the support of our financial partners, a strong underlying business, and an unwavering focus on serving our customers around the world. Throughout this process, we expect to operate as usual while taking an important step toward emerging with a stronger financial foundation that will enable us to continue investing in innovation, supporting our customers, and executing our long-term strategy.”<\/p>\n\n\n\n

Continuity of Operations During Prepackaged Chapter 11 Process <\/strong><\/p>\n\n\n\n

The Company will continue operating in the ordinary course, with no anticipated disruption for employees, customers, suppliers, or business partners across global operations. To ensure a seamless transition into the prepackaged chapter 11 process, Alkegen has filed several customary \u201cFirst Day Motions.\u201d Among these customary motions is an “All Trade Motion,” which seeks authority to continue paying all trade creditors, vendors, and suppliers in the ordinary course pursuant to existing terms. Upon Court approval, these motions will enable the Company to continue its operations and uphold its commitments to employees, vendors, and customers. Alkegen expects to complete a quick, efficient court-supervised process in approximately 60 days. <\/p>\n\n\n\n

International Operations Through Prepackaged Chapter 11 <\/strong><\/p>\n\n\n\n

The prepackaged chapter 11 cases include Alkegen\u2019s U.S.-based operations and certain international entities, including those based in Canada, the United Kingdom, Germany, Luxembourg, the Netherlands, and Hong Kong. Importantly, none of Alkegen\u2019s international entities will conduct local insolvency proceedings in their respective jurisdictions. Business in these countries will continue to be conducted as usual with no impact on the Company\u2019s ability to deliver for customers or fulfill commitments to vendors.<\/p>\n\n\n\n

Luyang Energy-Saving Materials Co., Ltd. (\u201cLuyang\u201d) and its subsidiaries are not part of the U.S.-based restructuring process and will not be directly impacted by the chapter 11 cases. Luyang will continue to operate in the ordinary course, with no changes to management, operations, employees, customers, or supplier relationships. Luyang\u2019s status as a listed company will remain unaffected, and Alkegen will maintain its majority stake following completion of this process, with no ultimate controlling shareholders outside of the Company.<\/p>\n\n\n\n

Emerging Stronger<\/strong><\/p>\n\n\n\n

Upon emergence, Alkegen expects to have approximately $200 million in available liquidity and the financial flexibility to continue investing across its leading product portfolio. The Company is investing approximately $70 million in capital improvements in 2026, with an additional approximately $300 million anticipated through 2030. Upon completion of the restructuring, Alkegen will be owned by a group of leading institutional investors. With a stronger financial foundation, Alkegen will be well-positioned to enhance its leadership in specialty materials and thermal management and filtration solutions, invest in the next generation of its product offerings, and continue serving customers around the world.<\/p>\n\n\n\n

Additional information regarding Alkegen\u2019s chapter 11 process is available at alkegen.com\/financial-restructuring\/<\/a> and https:\/\/restructuring.ra.kroll.com\/Alkegen<\/a>. Stakeholders with questions may call Kroll at (888) 349-3237 (US and Canada toll free) and +1 (332) 230-1843 (International), or by emailing AlkegenInfo@ra.kroll.com<\/a>. <\/p>\n\n\n\n

Advisors <\/strong> <\/p>\n\n\n\n

Kirkland & Ellis LLP and Gray Reed are serving as legal counsel, Alvarez & Marsal is serving as financial advisor, Centerview Partners LLC is serving as investment banker, and C Street Advisory Group is serving as strategic communications advisor to the Company. Davis Polk & Wardwell LLP and PJT Partners are serving as advisors to the ad hoc group of lenders. <\/p>\n\n\n\n

About Alkegen<\/strong> <\/p>\n\n\n\n

Alkegen is a global leader in manufacturing high-performance fibrous materials, including refractory ceramic fiber, polycrystalline wool, aerogel composite and micro-fine glass, that are engineered into blankets, felts, papers, boards, complex shapes, and mats. Our products are used across steel and aluminum manufacturing, petrochemical refining, glass production, mineral processing, automotive emission control, electric vehicle and other battery safety, commercial building fire protection, aerospace insulation, advanced filtration, and other industries and applications. Alkegen leverages deep materials engineering expertise and high-specification manufacturing to deliver customized, mission-critical solutions that help the world breathe easier, live greener, and go further than ever before. Headquartered in Irving, Texas, the Company employs approximately 3,900 people across 23 countries and operates approximately 50 fully integrated global manufacturing facilities. More information is available at www.alkegen.com<\/a>. <\/p>\n\n\n\n

Contacts<\/strong>
C Street Advisory Group
alkegen@thecstreet.com<\/a><\/p>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

Company enters chapter 11 with overwhelming support from key financial partners, including 99% of first lien and 80% of second lien holders Expected to eliminate approximately $3.1 billion of debt…<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"class_list":["type-post"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/posts\/18252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/comments?post=18252"}],"version-history":[{"count":4,"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/posts\/18252\/revisions"}],"predecessor-version":[{"id":18256,"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/posts\/18252\/revisions\/18256"}],"wp:attachment":[{"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/media?parent=18252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/categories?post=18252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alkegen.com\/de\/wp-json\/wp\/v2\/tags?post=18252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}